NAV

Pharmacogenomics Documentation and Definitions

GenoBrowse is a pharmacogenetic/pharmacogenomic dataset of adverse drug reactions and other pharmacological effects related to individual genetic makeup. Some of the data has been extracted from literature and various online resources, while a large portion are inferred (see below) based on drug metabolism and known enzyme polymorphisms. Many of these inferred effects are important in predicting and understanding the mechanisms of adverse drug reactions (a significant cause of morbidity and mortality).

The dataset currently contains 324 directly studied effects (113 ADR, 211 general) and 5993 inferred effects (4356 ADR, 1668 general). Currently, 176 drugs have at least one recorded effect.

Type Definitions

TypeNameDefinition
ADRAdverse Drug ReactionAn effect that results in a negative clinical reaction when an individual with the given genotype is prescribed the given drug.
EffectGeneral EffectAn effect that can include therapeutic effects (e.g. better drug response) or recommendations for dose adjustment for individuals.
Directly StudiedDirectly Studied EffectEffects associated with drugs that have been directly studied for this particular polymorphism. These contain multiple references including official prescribing labels. Directly Studied effects are often used clinically in personalized medicine.
InferredInferred EffectInferred effects have been assigned to drugs based on similarity of SNP enzymatic effects. Drugs that have a confirmed effect with a specific genotype, are inferred to likely have the same effect with other genotypes which all confer a similar or identical enzymatic effect.

Notes

Some effects contain multiple RS IDs for a single entry. These effects represent haplotypes, combinations of SNPs that are often seen inherited together and are studied in this way. Each allele group contains a "signature SNP" (a SNP present in each group).

General References

Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001 Nov 14;286(18):2270-9. 11710893